Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $350
Madrigal Pharmaceuticals (MDGL) Gets a Buy From Oppenheimer
Express News | Madrigal Pharmaceuticals Inc : Oppenheimer Cuts Target Price to $350 From $375
H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Madrigal Pharmaceuticals' Promising Outlook: Buy Rating for Rezdiffra Amidst Enthusiastic Trial Enrollment and Regulatory Milestones
Express News | Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients With Compensated Nash/Mash Cirrhosis
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients With Compensated NASH/MASH Cirrhosis
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
Cantor Fitzgerald Reiterates Neutral on Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Analyst Ratings
Is Madrigal Pharmaceuticals (NASDAQ:MDGL) Using Debt In A Risky Way?
Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $336
Piper Sandler Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $415
Buy Rating on Madrigal Pharmaceuticals: Rezdiffra's Rising Prescription Rates and Blockbuster Potential Drive Positive Outlook
Express News | Madrigal Pharmaceuticals Appoints DR. Michael R. Charlton as Senior Vice President, Clinical Development
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
Madrigal Pharmaceuticals Announces Publication Of Health-Related Quality Of Life Results From The Phase 3 MAESTRO-NASH Trial Of Rezdiffra
Express News | Madrigal Pharmaceuticals Inc - Rezdiffra Achieves Primary Endpoints in Phase 3 Trial